Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | Treatment of patients with SCD who are not eligible for transfusion

Lewis Hsu • 26 Oct 2023
ASCAT 2023
Non-Malignant Sickle Cell Disease Crizanlizumab Hydroxyurea L-glutamine Voxelotor

Lewis Hsu, MD, PhD, University of Illinois at Chicago, Chicago, IL, discusses how clinicians can manage and treat patients with sickle cell disease (SCD) who are ineligible for transfusion and briefly outlines the aims of some current clinical trials in SCD treatment. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lewis Hsu

1:01
Addressing racism and stigma in the fields of SCD and thalassemia
Lewis Hsu • 26 Oct 2023
2:10
An update on the treatment of SCD
Lewis Hsu • 26 Oct 2023
1:01
Prophylactic antibiotic use prior to dental treatment in SCD patients
Lewis Hsu • 26 Oct 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals